Leading pharmacy benefit managers are shifting away from lucractive rebates on biologic drugs and toward lower-cost ...

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials. Check ...

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found ...

AbbVie has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection in ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

UnitedHealth Group, Eli Lilly and Company, Walmart, Johnson & Johnson, AbbVie, McKesson, and Boston Scientific are the seven Medical stocks to watch today, according to MarketBeat’s stock screener ...

AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.